Cargando…
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis
INTRODUCTION: No clinically useful predictive factor has been yet identified for treatment of metastatic pancreatic cancer (mPC). It is noteworthy that FOLFIRINOX, despite its high toxicity, is effective only in some patients. We retrospectively analyzed expression of excision repair cross-complemen...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085217/ https://www.ncbi.nlm.nih.gov/pubmed/27147577 http://dx.doi.org/10.18632/oncotarget.9063 |
_version_ | 1782463531394793472 |
---|---|
author | Strippoli, Antonia Rossi, Sabrina Martini, Maurizio Basso, Michele D'Argento, Ettore Schinzari, Giovanni Barile, Rosalba Cassano, Alessandra Barone, Carlo |
author_facet | Strippoli, Antonia Rossi, Sabrina Martini, Maurizio Basso, Michele D'Argento, Ettore Schinzari, Giovanni Barile, Rosalba Cassano, Alessandra Barone, Carlo |
author_sort | Strippoli, Antonia |
collection | PubMed |
description | INTRODUCTION: No clinically useful predictive factor has been yet identified for treatment of metastatic pancreatic cancer (mPC). It is noteworthy that FOLFIRINOX, despite its high toxicity, is effective only in some patients. We retrospectively analyzed expression of excision repair cross-complementing group-1 (ERCC1) - involved in the repair of platinum induced damage - in patients affected by mPC treated with FOLFIRINOX in order to evaluate its predictive role. RESULTS: FOLFIRINOX resulted more effective in patients with normal ERCC1 levels than in those with ERCC1 hyper-expression. Median progression free survival (PFS) was 11 vs. 4 months (HR 0.26; 95% CI 0.14-0.50; p<.0001), median overall survival (OS) 16 vs. 8 months (HR 0.23; 95% CI 0.12-0.46; p<.0001) and disease control rate (DCR) 93% vs. 50% (p=0.00006). The advantage was confirmed at univariate and multivariate analysis. PATIENTS AND METHODS: 71 patients with histologically proven mPC and treated with FOLFIRINOX as first-line therapy were considered eligible. mRNA ERCC1 expression was determined using RT-PCR analysis. DISCUSSION: ERCC1 might be an effective predictor of response to FOLFIRINOX in mPC. Patients overexpressing ERCC1 should be excluded by this often toxic therapy and referred to an alternative treatment. |
format | Online Article Text |
id | pubmed-5085217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-50852172016-10-31 ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis Strippoli, Antonia Rossi, Sabrina Martini, Maurizio Basso, Michele D'Argento, Ettore Schinzari, Giovanni Barile, Rosalba Cassano, Alessandra Barone, Carlo Oncotarget Research Paper INTRODUCTION: No clinically useful predictive factor has been yet identified for treatment of metastatic pancreatic cancer (mPC). It is noteworthy that FOLFIRINOX, despite its high toxicity, is effective only in some patients. We retrospectively analyzed expression of excision repair cross-complementing group-1 (ERCC1) - involved in the repair of platinum induced damage - in patients affected by mPC treated with FOLFIRINOX in order to evaluate its predictive role. RESULTS: FOLFIRINOX resulted more effective in patients with normal ERCC1 levels than in those with ERCC1 hyper-expression. Median progression free survival (PFS) was 11 vs. 4 months (HR 0.26; 95% CI 0.14-0.50; p<.0001), median overall survival (OS) 16 vs. 8 months (HR 0.23; 95% CI 0.12-0.46; p<.0001) and disease control rate (DCR) 93% vs. 50% (p=0.00006). The advantage was confirmed at univariate and multivariate analysis. PATIENTS AND METHODS: 71 patients with histologically proven mPC and treated with FOLFIRINOX as first-line therapy were considered eligible. mRNA ERCC1 expression was determined using RT-PCR analysis. DISCUSSION: ERCC1 might be an effective predictor of response to FOLFIRINOX in mPC. Patients overexpressing ERCC1 should be excluded by this often toxic therapy and referred to an alternative treatment. Impact Journals LLC 2016-04-27 /pmc/articles/PMC5085217/ /pubmed/27147577 http://dx.doi.org/10.18632/oncotarget.9063 Text en Copyright: © 2016 Strippoli et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Strippoli, Antonia Rossi, Sabrina Martini, Maurizio Basso, Michele D'Argento, Ettore Schinzari, Giovanni Barile, Rosalba Cassano, Alessandra Barone, Carlo ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis |
title | ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis |
title_full | ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis |
title_fullStr | ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis |
title_full_unstemmed | ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis |
title_short | ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis |
title_sort | ercc1 expression affects outcome in metastatic pancreatic carcinoma treated with folfirinox: a single institution analysis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085217/ https://www.ncbi.nlm.nih.gov/pubmed/27147577 http://dx.doi.org/10.18632/oncotarget.9063 |
work_keys_str_mv | AT strippoliantonia ercc1expressionaffectsoutcomeinmetastaticpancreaticcarcinomatreatedwithfolfirinoxasingleinstitutionanalysis AT rossisabrina ercc1expressionaffectsoutcomeinmetastaticpancreaticcarcinomatreatedwithfolfirinoxasingleinstitutionanalysis AT martinimaurizio ercc1expressionaffectsoutcomeinmetastaticpancreaticcarcinomatreatedwithfolfirinoxasingleinstitutionanalysis AT bassomichele ercc1expressionaffectsoutcomeinmetastaticpancreaticcarcinomatreatedwithfolfirinoxasingleinstitutionanalysis AT dargentoettore ercc1expressionaffectsoutcomeinmetastaticpancreaticcarcinomatreatedwithfolfirinoxasingleinstitutionanalysis AT schinzarigiovanni ercc1expressionaffectsoutcomeinmetastaticpancreaticcarcinomatreatedwithfolfirinoxasingleinstitutionanalysis AT barilerosalba ercc1expressionaffectsoutcomeinmetastaticpancreaticcarcinomatreatedwithfolfirinoxasingleinstitutionanalysis AT cassanoalessandra ercc1expressionaffectsoutcomeinmetastaticpancreaticcarcinomatreatedwithfolfirinoxasingleinstitutionanalysis AT baronecarlo ercc1expressionaffectsoutcomeinmetastaticpancreaticcarcinomatreatedwithfolfirinoxasingleinstitutionanalysis |